Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Primary hyperparathyroidism and malignancy: "studies by nature".

Udi Cinamon1, Robert E Turcotte

  • 1Department of Otolaryngology, Head and Neck Surgery, Edith Wolfson Medical Center, Holon, 98100, Israel. udicin@yahoo.com

Bone
|March 15, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Conservative Management of Primary Thyroid Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma: A Case Report and Review of Multidisciplinary Approach.

Cureus·2026
Same author

Aberrant EZHIP expression drives tumorigenesis in osteosarcoma.

Nature communications·2025
Same author

Taper Junction Subsidence Occurs in Modular Tumor Endoprostheses: How Concerned Should We Be?

Clinical orthopaedics and related research·2024
Same author

Clinical impact of whole-body MRI in staging and surveillance of patients with myxoid liposarcoma: a 14-year single-centre retrospective study.

European radiology·2024
Same author

Patient-physician agreement on function and pain is associated with long-term outcomes in sarcoma: findings from a longitudinal study.

Journal of cancer survivorship : research and practice·2023
Same author

Primary Sarcomas of the Spine: A Systematic Review and Pooled Data Analysis.

Clinical spine surgery·2023
Same journal

Diagnosis and management of X-linked hypophosphatemia in dental practice: A scoping review.

Bone·2026
Same journal

Baseline β-CTX and BMI predict suitability for deferred zoledronic acid redosing beyond 12 months in postmenopausal Indian women with osteoporosis.

Bone·2026
Same journal

Bone density-based maturation of the midpalatal suture in children aged 8-15 years.

Bone·2026
Same journal

Disrupted phosphate metabolism and SIBLING/ASARM peptide accumulation underlie impaired bone mineralization in klotho-deficient (kl/kl) mice.

Bone·2026
Same journal

Linking genetic variants to bone microstructure: Histological signatures of osteogenesis imperfecta subtypes.

Bone·2026
Same journal

The impact of alcohol consumption on bone mineral density: Insights from cross-sectional and Mendelian randomization studies.

Bone·2026
See all related articles

This study found no clear link between parathyroid hormone (PTH) and cancer, including osteosarcoma, in patients with hyperparathyroidism or osteosarcoma. Further research may be needed before PTH therapy for osteoporosis.

Area of Science:

  • Endocrinology
  • Oncology
  • Bone Metabolism

Background:

  • Parathyroid hormone (PTH) is approved for osteoporosis treatment.
  • Concerns exist regarding a potential association between PTH and cancer, particularly osteosarcomas.

Purpose of the Study:

  • To investigate the relationship between primary hyperparathyroidism and cancer incidence.
  • To evaluate the association between osteosarcomas and hyperparathyroidism.

Main Methods:

  • Retrospective review of medical records for 582 patients with primary hyperparathyroidism (Cohort 1).
  • Retrospective review of medical records for 126 patients with osteosarcoma (Cohort 2).
  • Analysis of malignancy and hyperparathyroidism incidence and history.

Related Experiment Videos

Main Results:

  • 9.6% of hyperparathyroidism patients had malignancy; 8% developed cancer post-diagnosis, a rate not exceeding the general population.
  • No osteosarcomas were found in the hyperparathyroidism cohort.
  • No hyperparathyroidism was documented in the osteosarcoma cohort.
  • No clear association was found between primary hyperparathyroidism and cancer, or between osteosarcomas and hyperparathyroidism.

Conclusions:

  • The study did not find a demonstrable association between primary hyperparathyroidism and cancer risk.
  • No link was established between osteosarcomas and hyperparathyroidism.
  • Pre-treatment screening for neoplasms may be advisable before PTH administration due to potential tumor invasiveness.